免疫检查点抑制剂在胃肠道肿瘤治疗的研究进展及安全性探讨  

Research progress and safety of immune checkpoint inhibitors in the treatment of gastrointestinal neoplasms

作　　者：庄奕翔 林高枫 许国玺[1] 王怀帅[1] 蔡志聪 李银林 林奇忆 刘维波[1] Zhuang Yixiang;Lin Gaofeng;Xu Guoxi;Wang Huaishuai;Cai Zhicong;Li Yinlin;Lin Qiyi;Liu Weibo(Department of Gastroenterology,Jinjiang Hospital,Quanzhou 362200,China)

机构地区：[1]晋江市医院胃肠外科,泉州362200

出　　处：《中国医师杂志》2022年第3期338-340,345,共4页Journal of Chinese Physician

摘　　要：胃肠道肿瘤是最常见的消化道恶性肿瘤,其发病率呈逐年上升趋势。相对于其他实体肿瘤,胃肠道肿瘤中免疫检查点抑制剂的应用仍处于不断探索阶段。本文拟盘点免疫检查点抑制剂在晚期胃癌、错配修复功能缺陷/微卫星高度不稳定及错配修复功能完整/微卫星稳定或微卫星低度不稳定两大类结直肠癌治疗中的相关研究与最新进展,并结合相关研究进一步评估免疫治疗的有效性、安全性。Gastrointestinal neoplasms is the most common digestive tract neoplasms,and its incidence rate is increasing year by year.Compared with other solid tumors,the application of immune checkpoint inhibitors in gastrointestinal neoplasms is still in the stage of continuous exploration.This paper intends to review the relevant research and latest progress of immune checkpoint inhibitors in advanced gastric cancer,mismatch repair function defect/microsatellite high instability and mismatch repair function integrity/microsatellite stability or microsatellite low instability,and further evaluate the effectiveness and safety of immunotherapy combined with relevant studies.

关 键 词：胃肠肿瘤 免疫检查点抑制剂 程序性细胞死亡受体1 微卫星不稳定性 

分 类 号：R735[医药卫生—肿瘤]